循环肿瘤DNA在结直肠癌中的应用:当前与实践进展
循环肿瘤DNA(ctDNA)是结直肠癌有前景的预后乃至预测生物标志物,可用于微小残留病(MRD)检测、早期复发监测、分子分型和疗效预测。CIRCULATE、COBRA、Dynamic II/III和ACT3等前瞻性研究正在MRD场景中评估ctDNA指导临床决策的作用,不同ctDNA液体活检平台各有优劣。
要点
- ctDNA在结直肠癌中具有预后价值,并可能作为预测生物标志物。
- ctDNA应用包括MRD检测、早期复发监测、分子分型和疗效预测。
- CIRCULATE、COBRA、Dynamic II/III和ACT3等前瞻性研究正在评估ctDNA指导临床决策。
核心结论
- ctDNA是结直肠癌个性化管理中有前景的预后生物标志物,并可能具有预测价值。
- 需要前瞻性研究明确ctDNA应如何及在何处用于临床决策。
研究设计与样本
- 综述,概述ctDNA在结直肠癌中当前和不断发展的应用。
- 文中提及CIRCULATE、COBRA、Dynamic II/III和ACT3等前瞻性研究正在MRD场景中进行。
主要发现
- 结直肠癌因循环肿瘤片段(细胞、DNA、甲基化标志物等)脱落量大,特别适合基于液体活检的方法。
- ctDNA已显示多种潜在应用,包括检测MRD、监测早期复发、分子分型和治疗反应预测。
- ctDNA的用途已从最初用于晚期/转移性场景的分子分型和获得性耐药机制检测,扩展到识别MRD及早期检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There exists a tremendous opportunity in identifying and determining the appropriate predictive and prognostic biomarker(s) for risk stratification of patients with colorectal cancers (CRCs). Circulating tumor DNA (ctDNA) has emerged as a promising prognostic and possibly predictive biomarker in the personalized management of patients with CRCs. The disease is particularly suited to a liquid biopsy-based approach since there is a great deal of shedding of circulating tumor fragments (cells, DNA, methylation markers, etc). ctDNA has been shown to have several potential applications, including detecting minimal residual disease (MRD), monitoring for early recurrence, molecular profiling, and therapeutic response prediction. The utility of ctDNA has broadened from its initial use in the advanced/metastatic setting for molecular profiling and detection of acquired resistance mechanisms, toward identifying MRD, as well as early detection. Prospective studies such as CIRCULATE, COBRA, Dynamic II/III, and ACT3 are underway in the MRD setting to further understand how ctDNA may be used to inform clinical decision making using both tumor-informed and tumor-agnostic platforms. These prospective studies use ctDNA to guide management of patients with CRC and will be critical to help guide how and where ctDNA should or should not be used in clinical decision making. It is also important to understand that there are different types of ctDNA liquid biopsy platforms, each with advantages and disadvantages in different clinical indications. This review provides an overview of the current and evolving use of ctDNA in CRC.
引用
- Malla M, Loree JM, Kasi PM, et al. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. J Clin Oncol. 2022. PMID: 35839443. doi:10.1200/JCO.21.02615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。